Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in type 2 diabetes with cardiovascular disease and hypertension
2009-016791-71Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM), hypertension (HTN) and cardiac morbidity comparing Dapagliflozin 10 mg once daily with Placebo once daily (2 arms). Primary endpoint: Change in seated systolic blood pressure at week 8. Started Dec 2009; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)hypertension (HTN)cardiac morbidity
Beyond the preview
Go deeper on 2009-016791-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016791-71.